Supplementary Online Content

Howard JF Jr, Nowak RJ, Wolfe GI, et al; the Zilucoplan MG Study Group. Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. Published online February 17, 2020. *JAMA Neurol.* doi:10.1001/jamaneurol.2019.5125

eTable 1. Efficacy of Zilucoplan Is Independent of Prior Therapies

eTable 2. Treatment-Emergent AEs and Injection-Site Reactions

eFigure 1. Change From Baseline Over 12 Weeks for 0.1 mg/kg Zilucoplan and Placebo in (A) QMG (B) MG-ADL, (C) MG-QoL15r, and (D) MGC Scores

eFigure 2. Radar Plots Suggest Consistency of Improvement Across All 4 End Points When Treated With (A) 0.3 mg/kg Zilucoplan Daily Subcutaneously vs (B) Placebo.

eFigure 3. Mean Complement Activity as Measured by Sheep Red Blood Cell Assay (% Hemolysis)

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Efficacy of Zilucoplan Is Independent of Prior Therapies
--


	Treatment Interaction <i>P</i> Value (zilucoplan 0.3 mg/kg vs placebo)				
Prior Therapy	QMG	MG-ADL	MGC	MG-QoL15r	
IST	0.59	0.43	0.62	0.62	
IVIg	0.74	0.68	0.64	0.77	
PLEX	0.21	0.49	0.29	0.45	

Abbreviations: IST, immunosuppressive therapy; IVIg, intravenous immunoglobulin; MG-ADL, Myasthenia Gravis Activities of Daily Living; MGC, Myasthenia Gravis Composite; MG-QoL15r, Myasthenia Gravis Quality-of-Life revised scale; PLEX, plasma exchange; QMG, Quantitative Myasthenia Gravis.

eTable 2. Treatment-Emergent AEs and Injection-Site Reactions


Patients, n	Placebo (n = 15)	Zilucoplan 0.1 mg/kg (n = 15)	Zilucoplan 0.3 mg/kg (n = 14)
Patients with AEs	12	15	12
Patients with treatment-related AEs	3	8	3
Patients with serious AEs	3	0	5
Patients with treatment-related serious AEs	0	0	0
Patients with most common treatment-related AEs ^a			
Nausea	0	2	0
Injection-site bruising	1	2	0
Injection-site scab	0	3	0
Contusion	0	1	1
Headache	1	4	2
Patients with injection-site reactions	2	4	3


^aOccurring in >1 patient. Abbreviation: AE, adverse event.




eFigure 1. Change From Baseline Over 12 Weeks for 0.1 mg/kg Zilucoplan and Placebo in (A) QMG (B) MG-ADL, (C) MG-QoL15r, and (D) MGC Scores

Blue shading highlights the delayed onset of clinical effect of the 0.1-mg/kg dose of zilucoplan as compared to the 0.3-mg/kg dose (Figure 2). **P* < 0.10. CFB, change from baseline; MG-ADL, Myasthenia Gravis Activities of Daily Living; MGC, Myasthenia Gravis Composite; MG-QoL15r, Myasthenia Gravis Quality-of-Life revised scale; QMG, Quantitative Myasthenia Gravis; SEM, standard error of the mean.





The outermost line on each radar plot represents the baseline (bold dark blue; ie, "0' for all end points), and each concentric dashed square represents a reduction from baseline by 2 points. The center of each plot represents a reduction of 8 points. Mean CFB values for QMG, MGC, and MG-QoL15r are shown. Given the lower dynamic range of the MG-ADL, 2x MG-ADL is represented on the graphs for illustrative purposes. CFB at 12 weeks (bold red) and other time points are as indicated. 2x MG-ADL, 2-fold mean MG-ADL; CFB, change from baseline; MG-ADL, Myasthenia Gravis Activities of Daily Living; MGC, Myasthenia Gravis Composite; MG-QoL15r, Myasthenia Gravis Quality-of-Life revised scale; QMG, Quantitative Myasthenia Gravis.



eFigure 3. Mean Complement Activity as Measured by Sheep Red Blood Cell Assay (% Hemolysis)

LLOQ, lower limit of quantification.